For the quarter ending 2026-03-31, ERNAW had $7,293K increase in cash & cash equivalents over the period. -$2,266K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Gain on lease termination | - | 0 |
| Impairment of right-of-use asset | - | 33 |
| Paid-in-kind interest expense | - | 0 |
| Loss on disposal of fixed assets | - | -13 |
| Amortization of debt discount and debt issuance costs | - | 0 |
| Accrued interest expense | 0 | 22 |
| Change in fair value of contingent consideration liability | - | 0 |
| Other receivables | 0 | -342 |
| Deferred revenue | - | 0 |
| Other non-current assets | 0 | -8 |
| Change in fair value of convertible notes | - | 0 |
| Forward sales contract expense | 0 | -5,800 |
| Fair value adjustments to bridge notes derivative liability | - | 0 |
| Change in fair value of warrant liabilities | 0 | -1 |
| Depreciation and amortization | 8 | 65 |
| Issuance of common stock in connection with settlement | - | 69 |
| Stock-based compensation | 309 | 1,496 |
| Issuance of common stock to consultant for services | 96 | 141 |
| Prepaid expenses and other current assets | 320 | 268 |
| Accounts payable and accrued expenses | 759 | 60 |
| Operating lease liability | -75 | -208 |
| Due from related party | -750 | 750 |
| Due to related party | -500 | 750 |
| Other liabilities | 93 | 15 |
| Net Income Loss | -5,500 | -14,100 |
| Gains Losses On Extinguishment Of Debt | - | 800 |
| Goodwill Impairment Loss | 2,000 | - |
| Amortization of right-of-use asset | 78 | 198 |
| Net cash used in operating activities | -2,264 | -7,017 |
| Proceeds received from the convertible notes financing | - | 0 |
| Proceeds received from the sale of fixed assets | - | 0 |
| Fees paid related to the convertible notes financing | - | 0 |
| Purchase of property and equipment | 2 | 37 |
| Proceeds received from bridge notes financing | - | 0 |
| Net cash used in investing activities | -2 | -37 |
| Proceeds received from notes payable | 0 | 2,250 |
| Gross proceeds received from the sale of common stock, prefunded warrants and milestone warrants in public offering | 10,480 | 4,929 |
| Fees related to public offering | 939 | - |
| Gross proceeds received from the exercise of prefunded warrants | 20 | 30 |
| Fee related to the exercise of prefunded warrants from public offering | 2 | 0 |
| Net cash provided by financing activities | 9,559 | 7,209 |
| Net increase in cash | 7,293 | 155 |
| Net increase in cash | 7,293 | 155 |
| Cash at beginning of period | 1,884 | 1,729 |
| Cash at end of period | 9,177 | 1,884 |
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)